Navigation Links
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Date:11/2/2011

NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export (SINE) for various cancers.  The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

Michael Kauffman, MD, PhD, Karyopharm's CEO, remarked, "This funding shows the confidence our investors have in our progress and platform. With these additional resources, we are able to move our oral clinical SINE compound for oncology into Phase I studies in both hematologic and solid tumor malignancies. The oral bioavailability and preliminary tolerability of the compounds allow us to investigate these agents for indications outside of cancer, including autoimmune, inflammatory and viral disorders.  We look forward to bringing the first SINE therapeutic to patients with cancer in the coming year."

Karyopharm is the leader in the development of nuclear transport modulators for the treatment of cancer, autoimmune, dermatologic, and viral diseases. These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in a variety of animal models.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham, Michael Kauffman, Giulio Draetta and Ronald DePinho in 2008.  Karyopharm completed a $20M Series A financing in October, 2010. The Company has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. By inhibiting the nuclear export of tumor suppressor proteins, Karyopharm's drug candidates force the activation of the cell's key tumor suppressor and anti-inflammatory pathways including p53, p21, pRB, FoxO, and the inhibitor of NF-kB (i.e., IkB).  Karyopharm anticipates entering the clinic in 2012 with its first oral SINE compound for the treatment of various cancers.  The Company is also evaluating the use of SINE in autoimmune, viral and dermatologic disorders.  Karyopharm Therapeutics is located in Natick, Massachusetts.

Contact: Michael Kauffman, +1-508-975-4821, mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
6. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
7. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
8. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
9. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
10. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in ... its customers three new solutions for measurements where traditional cuvette applications are not ... customer has an oddly-shaped sample that would not fit into a typical cuvette ...
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting in ... more. In addition to these improvements, the latest release brings enhanced data ...
(Date:1/11/2017)... YORK , Jan. 11, 2017  Brian Mehling, ... and founder of Blue Horizon International (BHI), will be ... Davos from January 17-20, 2017. ... global conference. The theme of this year,s ... the program,s 400 sessions will address strategies for fostering ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):